Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Novo still maintains a 65% market share in global GLP-1 volume
Cardiovascular safety data from published trials showed reductions in systolic blood pressure (ranging from 4.3 to 7.9 mmHg depending on dose) and diastolic blood pressure (2.3 to 4.6 mmHg reductions)
The specific impacts to any one plan or organization boils down to whether they cover GLP-1s for weight loss purposes
GLP-1 Weight Loss Program Provider-prescribed semaglutide or tirzepatide as low as $194/mo* Full-dose GLP-1 therapy with ongoing provider support designed for meaningful, sustainable weight loss
How Virtual Weight Loss Care Works 1
US$ 23.40
US$ 21.61
US$ 28.99
US$ 25.23
